Clinical trials: Crohn's Disease (CD)
Crohn's Disease
A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence
REMICADE (infliximab) is a drug used to treat active Crohn's disease and is being tested in an experiment to see if it may be useful in preventing relapse of Crohn's disease after surgical resection.
- Trial name
- NCT01190839
- Testing
- Infliximab
- Where
- 142 sites in United States, Australia and 12 more
- Volunteers
- 297 people
- Sponsor
- Janssen Biotech, Inc.
Ulcerative Colitis, Crohn's Disease
A Study of Vedolizumab in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) in the Community Setting
Ulcerative Colitis (UC) and Crohn's Disease (CD) are long-term conditions in the gut that can cause diarrhea, swelling (inflammation), bleeding from the anus, and belly pain.
- Trial name
- PANORAMA (NCT06581328)
- Testing
- Vedolizumab IV, Vedolizumab SC
- Where
- 101 sites in United States
- Volunteers
- 200 people
- Sponsor
- Takeda
Crohn Disease (CD)
HB-adMSCs for the Treatment of Crohn's Disease
Methodology: Randomized, double-blind, efficacy and safety study of allogeneic HB-adMSCs vs placebo for the treatment of Crohn's Disease with a 16-week treatment period and a safety and efficacy follow up period for 52 weeks post…
- Trial name
- NCT07077746
- Testing
- HB-adMSCs - Hope Biosciences Adipose Derived Mesenchymal Stem Cells, 0.9% sodium chloride
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- Hope Biosciences Research Foundation
Crohn's Disease
Efficacy and Safety Study of Ontamalimab as Maintenance Treatment in Participants With Moderate to Severe Crohn's Disease (CARMEN CD 307)
The purpose of this study is to evaluate the efficacy and safety of ontamalimab as maintenance treatment in participants with moderate to severe Crohn's disease (CD).
- Trial name
- CARMEN CD 307 (NCT03627091)
- Testing
- Ontamalimab
- Where
- 281 sites in United States, Argentina and 32 more
- Volunteers
- 40 people
- Sponsor
- Shire
Ulcerative Colitis, Crohn Disease
Microbial and Human Determinants of the Onset of IBD Flares
This is a longitudinal, observational study that aims to identify the microbial and human molecular triggers of IBD flares via stool, saliva, and blood metatranscriptomes, whole blood proteome, and collected clinical metadata.
- Conditions
- Ulcerative Colitis, Crohn Disease, Irritable Bowel, Crohns Disease Aggravated
- Trial name
- NCT05463900
- Where
- United States
- Volunteers
- 2,000 people
- Sponsor
- Viome
Crohn's Disease
A Study of Subcutaneous HUMIRA (Adalimumab) Injection to Assess Adverse Events and Change in Disease Activity In Adult Participants With Moderate to Severe Active Crohn's Disease (CD)
Crohn's disease (CD) is an incurable chronic inflammatory disorder of the gastrointestinal tract. This study will assess how safe and effective Humira (adalimumab) is in treating moderately to severely active CD in China.
- Trial name
- NCT05394805
- Where
- 10 sites in China
- Volunteers
- 156 people
- Sponsor
- AbbVie
Crohn Disease
A Study to Test Whether BI 706321 Combined With Ustekinumab Helps People With Crohn's Disease
This study is open to adults, aged 18-75 years, with moderate to severe Crohn's disease. The purpose of this study is to find out whether BI 706321 combined with ustekinumab helps people with Crohn's disease.
- Trial name
- NCT04978493
- Testing
- BI 706321, Ustekinumab
- Where
- 49 sites in United States, Belgium and 9 more
- Volunteers
- 49 people
- Sponsor
- Boehringer Ingelheim
Ulcerative Colitis, Crohn's Disease
A Long-Term Extension Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis (UC) or Crohn's Disease (CD)
The main aim of this study is to learn about medical problems (adverse events) if vedolizumab subcutaneously (SC) is given to a child or teenager with UC or CD for a long time.
- Trial name
- NCT06405087
- Testing
- Vedolizumab SC, No Intervention
- Where
- 47 sites in United States, Belgium and 12 more
- Volunteers
- 70 people
- Sponsor
- Takeda
Arthritis, Rheumatoid (RA), Axial Spondyloarthritis (axSpA)
A Real-world Study of Imraldi® Use
The primary objective of this study is to evaluate candidate predictors of persistence on adalimumab (Imraldi®) participants diagnosed with immune-mediated inflammatory disease in Europe (EU).
- Conditions
- Arthritis, Rheumatoid (RA), Axial Spondyloarthritis (axSpA), Arthritis, Psoriatic (PsA), Crohn's Disease (CD)
- Trial name
- PROPER (NCT04089514)
- Testing
- Adalimumab
- Where
- 54 sites in Belgium, Germany and 4 more
- Volunteers
- 1,000 people
- Sponsor
- Biogen
Crohn's Disease
Blood and Stool Molecular Biomarkers Longitudinal Detection Study in Crohn's Disease (CD) Patients
To evaluate the relationship between noninvasive biomarkers (patient serological markers and metagenomic analysis of stool) and disease status as determined by colonoscopy and by clinical symptoms in patients with Crohn's…
- Trial name
- NCT03566407
- Testing
- Colonoscopy
- Where
- 5 sites in United States
- Volunteers
- 41 people
- Sponsor
- Prometheus Laboratories
Crohn Disease
Safety and Efficacy of EcoActive on Intestinal Adherent Invasive E. Coli in Patients With Inactive Crohn's Disease
This study will evaluate the safety of oral administration of EcoActive to patients with inactive Crohn's disease and how it affects the levels of AIEC in stool.
- Trial name
- NCT03808103
- Testing
- Bacteriophage preparation
- Where
- 2 sites in United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Intralytix, Inc.
IBD (Inflammatory Bowel Disease), IBS - Irritable Bowel Syndrome
ALPCO/Calprotectin CLIA Assay: Expected Values of Calprotectin in Healthy Subjects
This study is evaluating the levels of calprotectin, a protein found in stool, in healthy adults. Calprotectin is a marker of inflammation in the intestines and can help doctors tell the difference between inflammatory bowel…
- Conditions
- IBD (Inflammatory Bowel Disease), IBS - Irritable Bowel Syndrome, Crohn Disease (CD), UC - Ulcerative Colitis
- Trial name
- NCT07089420
- Testing
- ALPCO Calprotectin CLIA
- Where
- United States
- Volunteers
- 121 people, healthy volunteers welcome
- Sponsor
- American Laboratory Products Company
Crohn's Disease
Efficacy and Safety Study of Ontamalimab as Induction Therapy in Participants With Moderate to Severe Crohn's Disease (CARMEN CD 306)
The purpose of this study is to evaluate the efficacy and safety of Ontamalimab in inducing clinical remission and endoscopic response in participants with moderate to severe Crohn's Disease.
- Trial name
- CARMEN CD 306 (NCT03566823)
- Testing
- Ontamalimab
- Where
- 145 sites in United States, Argentina and 18 more
- Volunteers
- 34 people
- Sponsor
- Shire
Inflammatory Bowel Diseases, Colitis, Ulcerative
A Study of Moderate to Severe Inflammatory Bowel Disease, Including Ulcerative Colitis (UC) and Crohn's Disease (CD)
The main aim of this study is to check the disease activity in people with moderate to severe ulcerative colitis and Crohn's disease.
- Conditions
- Inflammatory Bowel Diseases, Colitis, Ulcerative, Crohn Disease
- Trial name
- RISE-MX (NCT04873700)
- Where
- 12 sites in Mexico
- Volunteers
- 335 people
- Sponsor
- Takeda
Crohn's Disease
Efficacy and Safety of Increased Dose of TA-650 (Infliximab) in Patients With Crohn's Disease (CD)
The purpose of this study is to assess the efficacy, safety and pharmacokinetics after administration of 10mg/kg TA-650 every 8 weeks to patients with Crohn's disease showing an insufficient response to previous treatment with 5…
- Trial name
- NCT00805766
- Testing
- TA-650
- Where
- 4 sites in Japan
- Volunteers
- 39 people
- Sponsor
- Tanabe Pharma Corporation
Crohn's Disease
Efficacy of CROWN in Repair and Maintenance of the Intestinal Mucosa in Patients With CD Receiving Anti-TNF Therapy
The purpose of this study is to evaluate CROWN's efficacy in supporting the repair and maintenance of the intestinal mucosa of patients with moderately to severely active Crohn's Disease receiving anti-Tumor Necrosis Factor (TNF)…
- Trial name
- PIONEER-CD (NCT02793778)
- Testing
- CROWN
- Where
- 39 sites in United States
- Volunteers
- 42 people
- Sponsor
- Prometheus Laboratories
Crohn's Disease
A Study to Evaluate the Safety of ALLO-ASC-CD for Treatment of Crohn's Disease
This is a phase I study to evaluate the safety of ALLO-ASC-CD for the treatment of crohn' disease. ALLO-ASC-CD is intravenous infusion containing allogenic adipose-derived mesenchymal stem cells.
- Trial name
- NCT02580617
- Testing
- ALLO-ASC
- Where
- South Korea
- Volunteers
- 9 people
- Sponsor
- Anterogen Co., Ltd.
Crohn Disease
Study to Evaluate the Efficacy and Safety of PF-06480605 in Adult Participants With Moderate to Severe Crohn's Disease
This Phase 2a, multicenter, randomized, double-blind, placebo-controlled study examines subcutaneous dose of PF-06480605 150 mg administered every 4 weeks in participants with moderate to severe active Crohn's Disease to…
- Trial name
- NCT05471492
- Testing
- Investigational Product
- Sponsor
- Telavant, Inc.
Crohn Disease (CD)
DB-3Q for the Treatment of Medically Refractory Crohn's Disease
This research study is studying DB-3Q as a possible treatment for medically refractory Crohn's disease. The purpose of this study is to research and evaluate safety and effectiveness of the administration of bone marrow…
- Trial name
- NCT07625293
- Testing
- DB-3Q
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Direct Biologics, LLC
Crohn Disease
ENTYVIO in Bio-naive Patients With Moderate/Severe Crohn's Disease (CD) in Daily Practice
The purpose of this study is to describe physician-reported clinical effectiveness outcomes, as determined by Harvey-Bradshaw Index (HBI) assessment, in biologic-naive participants with CD over 12 months following treatment…
- Trial name
- EARLY-CD (NCT04349449)
- Where
- 14 sites in Canada
- Sponsor
- Takeda